SLC5A2 and type 2 diabetes mellitus: Any patient with T1D or T2D who experiences nausea, vomiting, is generally unwell or develops a metabolic acidosis in the setting of SGLT2 inhibitor therapy, should undergo prompt evaluation of ketonuria/ketonaemia.